Universal Biosensors Raises AU$10 Million via Entitlement Offer
Universal Biosensors (ASX:UBI) raised AU$10 million through an entitlement offer, with a 77% take-up rate by existing shareholders, according to a Wednesday filing with the Australian bourse. The rema
Universal Biosensors Narrows Q1 Loss as Revenue Rises; Shares Fall 3%
Universal Biosensors (ASX:UBI) narrowed first-quarter net loss after tax to AU$3.4 million from AU$3.8 million a year earlier, according to a Thursday filing with the Australian bourse. The company's
Universal Biosensors Opens AU$10 Million Rights Issue
Universal Biosensors (ASX:UBI) on Friday opened a fully underwritten nonrenounceable rights issue of CHESS depositary interests to raise AU$10 million, according to a Friday filing with the Australian
Universal Biosensors to Raise AU$10 Million for Technology Development
Universal Biosensors (ASX:UBI) is seeking to raise about AU$10 million via a fully underwritten nonrenounceable rights issue of 66,666,667 CHESS depositary interests at AU$0.15 apiece. Proceeds will b
H&G High Conviction Reports Flat Performance for March Quarter
Microcap ASX investor H&G High Conviction (ASX:HCF) has posted its March quarterly update which shows flat performance for the quarter, compared to the ASX Small Ordinaries Accumulation Index, which r
Australian Shares Rise as Central Bank Maintains Interest Rates
Australian shares rose Tuesday as the country's central bank kept rates steady for the third straight month. The S&P/ASX 200 Index rose 27.40 points, or 0.4%, to 7,703.20. While the Reserve Bank of Au
Universal Biosensors Secures FDA Approval for Xprecia Prime, Paving Way for US Market Expansion
Melbourne-based medical company Universal Biosensors (ASX: UBI) has received two approvals from the US Food and Drug Administration (FDA) for its Xprecia Prime coagulation analyser as a class II device.
Universal Biosensors Secures US FDA Approval for Coagulation Analyzer Device; Shares Surge 78%
Universal Biosensors (ASX:UBI) secured approval from the US Food and Drug Administration to market and sell the Xprecia Prime blood coagulation analyzer device in the US, according to a filing with th
This ASX Healthcare Stock Is up 72% on FDA News and 'Historic Moment'
Universal Biosensors, Inc (ASX: UBI) shares are having a day to remember on Tuesday.
Universal Biosensors Narrows 2023 Loss on Absence of Impairment, Higher Revenue; Shares Down 6%
Universal Biosensors (ASX:UBI) said Friday it narrowed its 2023 loss per share to AU$0.03 from the prior year's AU$0.14. The year-ago figure included an impairment of definite-lived intangible assets
Universal Biosensors Grows H2 2023 Sales by 55%
Universal Biosensors (ASX:UBI) reported a 55% increase in second-half 2023 sales from H1. The company exceeded AU$1.0 million in monthly sales for the first time in December 2023, according to a Wedne
Universal Biosensors' Coagulation Analysis Device Gets Approval in Europe
Universal Biosensors (ASX:UBI) secured approval in Europe for the use of its XPrecia Prime 4U blood coagulation analysis device in a patient self-testing environment. The diagnostic device was granted
Universal Biosensors Secures Marketing Approval, First Order for Coagulation Analyzer Device in India
Universal Biosensors (ASX:UBI) secured regulatory approval from the Indian Central Drugs Standard Control Organization to market and sell its Xprecia Prime coagulation analyzer device in the country.
Universal Biosensors Secures First Major Tender to Supply Xprecia Prime in Italy
Universal Biosensors (ASX:UBI) secured its first major tender to supply Xprecia Prime in Italy, the electrochemical cell technology firm said Wednesday. The bid pertains to an initial span of two year
Australian Shares Flat Ahead of Central Bank Policy Meeting
Australian shares were flat with a positive bias on Monday as investors awaited the Reserve Bank of Australia's policy meeting this Tuesday. The S&P/ASX 200 Index inched up 6.80 points to 7,410.40. An
Universal Biosensors Narrows Net Loss 74% in H1
Universal Biosensors (ASX:UBI) narrowed its net loss attributable to members 74% in the first half of the year to AU$2.4 million or AU$0.01 losses per share, from AU$9.2 million or AU$0.05 losses per
Universal Biosensors (ASX:UBI) Launches PETRACKR Products for Dogs and Cats With Diabetes
Universal Biosensors (ASX:UBI) Submits Xprecia Prime 510K Application to US FDA
Universal Biosensors (ASX:UBI) Toasts a New Sentia Wine Test
Universal Biosensors Cut to Hold From Buy by Bell Potter >UBI.AU
Universal Biosensors Cut to Hold From Buy by Bell Potter >UBI.AU
No Data